AllDocs -> cancers

Technology Evaluation Center BlueCross BlueShield Association ® ® An Association of Independent Blue Cross and Blue Shield Plans ©2006 Blue Cross and Blue Shield Association. Reproduction without prior authorization is prohibited. 1 NOTICE OF PURPOSE: TEC Assessments are scientific opinions, provided solely for informational purposes. TEC Assessments should not be construed to suggest that the Blue Cross Blue Shield Association, Kaiser Permanente Medical Care Program or the TEC Program recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service; any particular course of treatment, procedure, or service; or the payment or non-payment of the technology or technologies evaluated. Assessment Program Volume 21, No. 6 August 2006 Executive Summary Background Various methods for ...

COLORECTAL CANCER Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa™) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects Amalia Azzariti, Letizia Porcelli, Jian-Ming Xu, Grazia Maria Simone, Angelo Paradiso www.wjgnet.com Amalia Azzariti, Letizia Porcelli, Grazia Maria Simone, Angelo Paradiso, Clinical Experimental Oncology Laboratory, National Cancer Institute, Bari, Italy Jian-Ming Xu, Beijing 307 Hospital Cancer Center, Beijing 100039, China Supported by grants from the Italian Association for Cancer Research (AIRC-2004) and from the Italian Ministry of Health, Project ex art.12, Region of Emilia Romagna RF02 Correspondence to: Angelo Paradiso, MD, Head Clinical Experimental Oncology Laboratory, National Cancer Institute, Via Amendola 209, 70125 Bari, Italy. a.p...

C LINICAL J OURNAL OF O NCOLOGY N URSING • V OLUME 5, N UMBER 1 • L ETTERS TO THE E DITOR 5 L ISA S CHULMEISTER , RN, MN, CS, OCN ® E DITOR L ETTERS TO THE E DITOR Readers Bring Attention to Value of Surgical Intervention in Treating Colon Cancer Some of the information provided in the article “Therapeutic Options for Advanced Colorectal Cancer ,” by Deborah T. Berg, RN, BSN, and Christine Lilienfeld, RN, BSN, OCN ® ( Clinical Journal of Oncology Nursing, Vol. 4, pp. 209–216), is disputable. Several points are not consistent with cur- rent publications and the standard of care for metastatic colon cancer ...

A Novel Biomarker for Diagnosis of Ulcerative Colitis and Colon Cancer Background Tropomyosins are microfilament-associated proteins found in all eukaryotes and have been implicated in autoimmune diseases such as ulcerative colitis. To date, eight different isoforms (hTM1, hTM2, hTM3, hTMsma, hTM5a, hTM5b, hTM4, and hTM5) have been identified. Although anti- tropomyosin autoantibodies have been detected in the sera of patients with ulcerative colitis, the autoantigen triggering the autoantibody response has not been definitively identified. Previous studies at UMDNJ have identified hTM5 as the predominant immunogen in ulcerative colitis patients. Ulcerative colitis is difficult to diagnose because its symptoms are similar to other intestinal disorders. Furthermore, about 5% of patients with ulcerative colitis develop colon cancer . Thus, the identification of the autoantigen(s), in particular, the specific ...

original article The new england journal of medicine n engl j med 350;20 www.nejm.org may 13, 2004 2050 A Comparison of Laparoscopically Assisted and Open Colectomy for Colon Cancer The Clinical Outcomes of Surgical Therapy Study Group* The preparation of this article was over- seen by the writing committee of the Clin- ical Outcomes of Surgical Therapy Study Group of the Laparoscopic Colectomy Trial (Heidi Nelson, M.D., Daniel J. Sargent, Ph.D., H. Sam Wieand, Ph.D., James Flesh- man, M.D., Mehran Anvari, M.D., Steven J. Stryker, M.D., Robert W. Beart, Jr., M.D., Michael Hellinger, M.D., Richard Flanagan, Jr., M.D., Walter Peters, M.D., and David Ota, M.D.), who assume responsibility for the overall content and integrity of the arti- cle. Address reprint requests to Dr. Heidi Nelson at the Division of Colon and Rectal ...

Corporate Medical Policy Colon Cancer Screening File Name: colon_cancer_screening Policy Number: SUR6164 Origination: 12/2000 Last Review: 4/2006 Next Review: 4/2008 Description of Procedure or Service When colorectal cancer is diagnosed at an early, localized state, five-year survival is 90%, yet only 37% of incident cases are diagnosed while still localized. The same methods used to detect colorectal cancers at early, curable stages can also identify and remove adenomas, which give rise to colorectal cancer . Methods for early detection can therefore actually prevent colorectal cancer . Definitions of Early Detection Methods are as follows: ? Fecal Occult Blood Test (FOBT) - FOBT is a laboratory procedure that refers to the implementa- tion of the protocol for collecting and testing six samples from three consecutive stools at home. ...

Colon Cancer Patients Who Stop Chemotherapy Double Death Rate New research indicates that as many as 30 percent of patients with stage III colon cancer who were prescribed six months of chemotherapy with a combination of 5-fluorouracil and leucovorin stopped their treatment prematurely. Stopping chemotherapy for colon cancer was shown to be equivalent to receiving no treatment at all. The findings add to the arsenal of reasons why colon cancer patients, and all cancer patients, need to complete their chemotherapy regimens whenever possible. Previous studies have shown that not completing chemotherapy regimens for breast cancer is associated with shorter survival. This is the first study to look at a link between mortality rates from colon cancer and treatment adherence. "The intuitive thinking is that if you complete most of a treatment regimen, you should get most of the treatment benefit," ...

Unexplained Inversion of the Incidence Ratio of Colon and Rectal Cancer among Men in East Germany Stang A 1 , Stabenow R 2 , Stegmaier C 3 , Eisinger B 2 , Bischoff-Hammes E 1,4 , Jöckel KH 4 1 Institute of Medical Epidemiology, Biometry and Informatics, Medical Faculty, Martin-Luther-University of Halle-Wittenberg, Magdeburger Str. 27, 06097 Halle, Germany 2 Common Cancer Registry of Berlin, Brandenburg, Mecklenburg-Vorpommern, Sachsen-Anhalt, and the Free States of Sachsen and Thüringen (GKR), Brodauer Str. 16-22, 12621 Berlin, Germany 3 Saarland Cancer Registry, Virchowstr. 7, 66119 Saarbrücken, Germany 4 Institute of Medical Informatics, Biometry and Epidemiology, University Hospital, University of Duisburg-Essen, Hufelandstr. 55, 45147 Essen, Germany ...

Cancer : Cancer is a common disease and is identified in 1 out of 3 Canadians in their lifetime. It begins as a change in a single cell and this cell multiplies and creates a small group of abnormal cells within a specific tissue. This uncontrolled growth can lead to the development of a tumour. The development of cancer is due to both genetic and non- genetic factors. Colon cancer is one of the more frequently seen types of cancers and is diagnosed in approximately 16,000 people in Canada every year. Most individuals who have colon cancer have not inherited a gene that has predisposed them to cancer . Their cancer is thought to occur by chance and the cause is unknown. It is estimated that only 5-10% of colon cancers are hereditary and said to “run in families”. Colorectal Cancer Cancer Genetics: Genes ...

Corporate Medical Policy Genetic Testing for Colon Cancer File Name: genetic_testing_for_colon_cancer Policy Number: MED1171 Origination: 5/2004 Last Review: 4/2006 Next Review: 4/2008 Description of Procedure or Service There are currently two well-defined types of hereditary colorectal cancer , familial polyposis (FAP) and hereditary non polyposis colorectal cancer (HNPCC). FAP is typically apparent by age 10. If left untreated, all affected individuals will go on to develop colorectal cancer . FAP accounts for 1% of colorectal cancer and may also be associated with osteomas of the jaw, skull, and limbs; sebaceous cysts; and pigmented spots on the retina, referred to as Gardner’s syndrome. Individuals with HNPCC tend to have early-onset colorec- tal cancer , right-sided tumors, and often multiple cancers. ...

What is colon cancer ? It is the growth of harmful cells in the rectum or large intestine ( colon ). What is a polyp? ? A polyp is a bump on the lining of the colon or rectum ? Left in place, some polyps may become a larger lump or cancer ? Colon cancer almost always starts with a polyp ? Early removal of a polyp stops the cancer before it starts (for both men and women) What are the signs of colon cancer ? ? Early screening is very important. There are usually no symptoms at first ? The number of cases of colon cancer rises greatly from age 50 to 70 Later you may have: ? Bloody or black, tarry stools ? Cramps or a full feeling ? A change in bowel habits ? Weight loss for no reason ? ...

6 th Annual National Colorectal Cancer Conference Finding HOPE: Healing, Options, Peer Support, Education September 15-17, 2006 Just outside of Chicago in Oak Brook, Illinois Richard Farrell Memorial Scholarship Fund Application Scholarship Guidelines: CCA is committed to making this event accessible to as many survivors, caregivers and advocates as possible based on the funding available. We will make every effort to assist all applicants based on their needs. The following guidelines apply: Scholarships will be limited to survivors, caregivers, CCA volunteers and those playing an integral role in the colorectal cancer community. Scholarships may apply to conference registration fee, travel and/or lodging expenses. No more than one scholarship will be awarded to an individual in any given year. All scholarship decisions are final. There is no appeal ...

Follow-up Regimen for Colon and Rectal Cancer Dennis L. Rousseau Jr. M.D./Ph.D., FACS Assistant Professor of Surgery Division of Surgical Oncology University of Texas Health Science Center San Antonio Page 2 Colorectal Cancer • 149,000 cases estimated for 2006 – 3 rd most common cancer of men and women • 55,200 deaths in 2006 – 2 nd most common cause of cancer death in men – 3 rd most common cause of cancer death in women • Lifetime incidence in US – Men – 1 in 17 – Women – 1 in 18 Jemal et al. CA Cancer J Clin 2006;56:106-130 Page 3 Colorectal Cancer • 65 – 70% cases treated with curative resection • 100,000 patients per year in need of follow-up • Stage I patients – 10-15% of cases – >90% 5-year ...

of the file http://www.stat.ohio-state.edu/~sabrina/presentation/bio882.ppt . G o o g l e automatically generates html versions of documents as we crawl the web. To link to or bookmark this page, use the following url: http://www.google.com/search?q=cache:JpaQJM0eOuUJ:www.stat.ohio-state.edu/~sabrina/presentation/bio882.ppt+colon+cancer+filetype:pdf+OR+filetype:doc+OR+filetype:ppt+OR+filetype:xls+OR+filetype:rtf&hl=it&ct=clnk&cd=334&lr=lang_en Google is neither affiliated with the authors of this page nor responsible for its content. These search terms have been highlighted: colon cancer 1581 Differential Expression in SAGE: Normal vs. Primary Colon Cancer Shuyan Wan Method Modified t-test (Baggerly 2003) Bayesian model based t-test (Vencio 2004) Both account for within-group biological variability and deal ...

BIOGRAPHY Dr Sarah Glover received her medical degree from Midwestern University in 1998 and completed training in internal medi- cine and gastroenterol- ogy at the University of Illinois at Chicago. Her current research focus is on the role of the extracellular matrix topography in post neoplastic trans- formation and metastasis in colon cancer . ABSTRACT Scanning electron microscope stereoscopy (SEM-S) has been used for many years to characterize 3D features of non-biological andbiological specimens. Traditionally, data production by SEM-S required tedious man- ual measurements. Digital image processing has led to the development of software for mathematically characterizing 3D surfaces. These programs greatly simplify SEM-S and provide details about features of a specimen including its area, volume, and roughness. We report the use of ...

465 Vol. 38, No. 7 Letters to the Editor 3. Starr S, Ferguson WJ, Haley HL, Quirk M. Community preceptors’views of their identi- ties as teachers. Acad Med 2003;78:820-5. 4. Bickel J, Brown AJ. Generation X: implica- tions for faculty recruitment and develop- ment in academic health centers. Acad Med 2005;80:205-10. Note: Further references are available from the authors of this letter. Recommendations for Colon Cancer Screening Questioned To The Editor: Recently, I read that in July 2005, the legal opinion of the American College of Gastroenterology (ACG) concluded that there is “‘potential litigation exposure’ inherent in credentialing physicians who lack board certification in gastroenterol- ogy or eligibility for such certifica- tion.” 1 “Turf wars” between family physicians and other subspecialties ...

Genetic Screening Model Identifies Colon Cancer Risk 06.28.06, 12:00 AM ET WEDNESDAY, June 28 (HealthDay News) -- Scottish researchers say they've developed a method that can better identify people at risk of certain types of hereditary colon cancer , as well as help guide treatment choices for those already diagnosed with colon cancer . In a study in the June 29 issue of the New England Journal of Medicine , the University of Edinburgh researchers detailed the two-stage screening model they developed to genetically identify those with hereditary cancers and the results of the study used to validate their model. "The method [we developed] allows rapid assessment of predicted likelihood that any given patient newly diagnosed with bowel cancer has a mutation," said one of the study's authors, Dr. Malcolm G. Dunlop, a professor of coloproctology and head of the Colon Cancer Genetics Group at Western ...

NP Poster 138 Colon Cancer Screening: knowledge, Attitudes, and Behavior Among African- American Women Jennifer Swedmark, ARNP MSN, Tallahassee, FL (email directed to dfrank@nursing.fsu.edu ); D. Frank, ARNP, PhD, Professor, Florida Sate University (FSU) Tallahassee, FL, L Grubbs, ARNP PhD, FSU PURPOSE: The purpose of this research was to investigate the frequency of colorectal cancer screening African-American women aged 50 and older who are in the high risk category for developing colorectal cancer and polyps. Additionally, their beliefs and attitudes were examined through the guidance of the Health Belief Model to aid in the prediction of screening utilization. METHODOLOGY: This randomized study used a descriptive/correlative, non-experimental survey approach. Participants were recruited through faith-based organizations in 4 quadrants of a north Florida city and were mailed the ...

Page 2 Mortality trends in England; ICD9 (153), ICD10 (C18); File: Sepho 96-04 V2 Colon cancer in England 1996 to 2004. Mortality trends Authors: Michael Goldacre, Marie Duncan, Paula Cook-Mozaffari, Matthew Davidson, Henry McGuiness, Daniel Meddings Published by: Unit of Health-Care Epidemiology, Oxford University, and South-East England Public Health Observatory, 2006 This document provides a profile of trends in mortality for colon cancer in England. The period covered is January 1 1996 to December 31 2004. The data are analysed from mortality files supplied to the South East England Public Health Observatories (SEPHO) by the Office for National Statistics (ONS). Mortality rates were calculated for the condition certified as the underlying cause of death and for the disease certified as any mention on the death certificates. Age-specific ...

0419 ZNF306, a novel zinc finger transcription factor, drives colon cancer progression Lin Yang, Stanley Hamilton, Lee Ellis, Gabriel Lopez-Bernstein, Angela Sanguino, Douglas Boyd MD Anderson Cancer Center, Houston, Texas, USA In colon cancer , simultaneous mutation of the APC , p53 and K- Ras genes is rare suggesting alternate genetic pathways. UniGene cluster analysis identified an EST, corresponding to a novel zinc finger protein (ZNF306) over-represented in colon cancer . RT-PCR confirmed elevated ZNF306 mRNA levels in 7/9 resected tumors. Stable ZNF 306 cDNA expression in HCT 116 colon cancer cells (wild type p53/APC), increased soft agar colony formation and 5FU-resistance. In vivo , ZNF306-overexpressing HCT 116 cells yielded larger tumors than control cells (100 and 20 % incidence respectively). Transduction of HT29 colon cancer cells with a ZNF306 ...

Nebraska Health and Human Services Nebraska Colon Cancer Screening Program 301 Centennial Mall South - P.O. Box 94817 Lincoln, NE 68509-4817 Toll Free: 1-800-532-2227 Fax: 471-0913 E-mail: ncp@hhss.ne.gov Website: www.hhss.ne.gov/crc CLIENT INFORMATION BOOKLET In this booklet you will find information on how Nebraska Colon Cancer Screening Program can serve you. Fecal Occult Blood T est Kit Colonoscopy Colon Health Screening Exams Version June 2006 Nebraska Colon Cancer Screening Program Page 2 What is the Nebraska Colon Cancer Screening Program (NCP)? NCP is the newest program added to Every Woman Matters (EWM). Nebraska is one of only five such programs in the nation. The goal of NCP is to increase screening for colon ...

For research use only A203( ? )- Colon cancer tissues_liver metastasis (formalin fixed) Specifications: • No. of cases: 18 • Tissue type: Colon cancer tissues_liver metastasis with corresponding colon normal tissues • No. of spots: 4 spots from each cancer case (72 spots) 18 non-neoplastic spots (18 spots) •Total spots: 90 • Corresponding normal tissues with cancers: Yes • Diameter: 1. 0 mm Documents : • Product specification: layout, summary of tissue spots • H&E stained images • Detailed pathological information Layout: 1 2 3 4 5 6 7 8 9 10 A B C D E F G H I : colon , non malignant : colon , tumor : liver, metastatic tumor : one patient case Page 2 ...

For research use only A203( ? ): Colon cancer tissues_liver metastasis (formalin fixed) Specifications: • No. of cases: 18 • Tissue type: Colon cancer tissues_liver metastasis with corresponding colon normal tissues • No. of spots: 4 spots from each cancer case (72 spots) 18 non-neoplastic spots (18 spots) •Total spots: 90 • Corresponding normal tissues with cancers: Yes • Diameter: 1. 0 mm Documents : • Product specification: layout, summary of tissue spots • H&E stained images • Detailed pathological information Layout: 1 2 3 4 5 6 7 8 9 10 A B C D E F G H I : colon , non malignant : colon , tumor : liver, metastatic tumor : one patient case A1 ...

For research use only A203( ? )- Colon cancer tissues_liver metastasis (formalin fixed) Specifications: • No. of cases: 14 • Tissue type: Colon cancer tissues_liver metastasis with corresponding normal tissues • No. of spots: 4 spots from each cancer case (56 spots) 14 non-neoplastic spots (14 spots) •Total spots: 70 • Corresponding normal tissues with cancers: Yes • Diameter: 1. 5 mm Documents : • Product specification: layout, summary of tissue spots • H&E stained images • Detailed pathological information Layout: 1 2 3 4 5 6 7 8 9 10 A B C D E F G : colon , non malignant : colon , tumor : liver, metastatic tumor : one patient case Page 2 Summary ...

For research use only A713( ? ):Test slide- Colon cancer tissues _liver metastasis (formalin fixed) Specifications: • No. of cases: 4 • Tissue type: Colon cancer tissues_liver metastasis with corresponding normal tissues • No. of spots: 4 spots from each cancer case (16 spots) 4 non-neoplastic spots (4 spots) •Total spots: 20 • Corresponding normal tissues with cancers: Yes • Diameter: 1. 5 mm Documents : • Product specification: layout, summary of tissue spots • H&E stained images • Detailed pathological information Layout: 1 2 3 4 5 A B C D : colon , non malignant : colon , tumor : liver, metastatic tumor : one patient case Page 2 Summary of tissue spots For research use ...

For research use only A203 ? - Colon cancer tissues (formalin fixed) Specifications: • No. of cases: 45 • Tissue type: Colon cancer tissues • No. of spots: 2 spots from each tumor case (90 spots) 8 non-neoplastic spots (8 spots) •Total spots: 98 • Corresponding normal tissues with cancers: No • Diameter: 1. 0 mm Documents : • Product specification: layout, summary of tissue spots • H&E stained images • Detailed pathological information Layout: Page 2 Summary of tissue spots For research use only (formalin fixed) A203 ? - Colon cancer tissues No Age Sex Keyword Differentiation Dukes stage 1 1,2 47 m Adenocarcinoma wd C2 2 3,4 64 m Adenocarcinoma wd B2 3 ...

Antiproliferative activity of PEP005, a novel agent that activates PKC d and inhibits PKCa, alone and in combination with cytotoxic agents in human solid tumor cancer cell lines Karim A. Benhadji 1 , Maria Serova 2 , Aïda Ghoul 1 , Esteban Cvitkovic 3 , Steven M. Ogbourne 4 , Peter Welburn 4 , Sandrine Faivre 5 , François Lokiec 1 , Fabien Calvo 2 , Eric Raymond 5 1 Department of clinical Pharmacology, Centre René Huguenin, Saint-Cloud, France; 2 INSERM U716 Saint-Louis Hospital, Paris; 3 CAC Oncology, Le Kremlin Bicetre, France; 4 Peplin Ltd., Newstead, Australia; 5 Department of Medical Oncology, Hopital Beaujon, Clichy, ...